Loading...
 
Back to the list
Mediterr J Rheumatol 2024;35(Suppl 1):20-6
Article Links
The Effect of JAK Inhibitors on Patient-Reported Outcomes in Psoriatic Arthritis
Sotirios G. Tsiogkas1, Carlo Perricone2, Dimitrios P. Bogdanos1
Authors Information

1Department of Rheumatology and Clinical Immunology, Faculty of Medicine, University of Thessaly, University General Hospital of Larissa, Greece

2Section of Rheumatology, Department of Medicine and Surgery, University of Perugia, Italy

SG Tsiogkas, C Perricone, DP Bogdanos

Keywords: patient-reported outcomes, tyrosine kinase 2, Janus kinase inhibitors, JAK, psoriatic arthritis
References
  1. FitzGerald O, Ogdie A, Chandran V, Coates LC, Kavanaugh A, Tillett W, et al. Psoriatic arthritis. Nat Rev Dis Prim [Internet] 2021;7:59. Available from: https://doi.org/10.1038/s41572-021-00293-y
  2. Karmacharya P, Chakradhar R, Ogdie A. The epidemiology of psoriatic arthritis: A literature review. Best Pract Res Clin Rheumatol [Internet] 2021;35:101692. Available from: https://doi.org/10.1016/j.berh.2021.101692
  3. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis [Internet] 2005;64:ii14 LP-ii17. Available from: http://ard.bmj.com/content/64/suppl_2/ii14.abstract
  4. Gudu T, Gossec L. Quality of life in psoriatic arthritis. Expert Rev Clin Immunol England 2018;14:405–17.
  5. Azuaga AB, Ramírez J, Cañete JD. Psoriatic Arthritis: Pathogenesis and Targeted Therapies. Int J Mol Sci 2023;24.
  6. Soomro M, Hum R, Barton A, Bowes J. Genetic Studies Investigating Susceptibility to Psoriatic Arthritis: A Narrative Review. Clin Ther [Internet] 2023;45:810–5. Available from: https://doi.org/10.1016/j.clinthera.2023.07.003
  7. Eder L, Law T, Chandran V, Shanmugarajah S, Shen H, Rosen CF, et al. Association between environmental factors and onset of psoriatic arthritis in  patients with psoriasis. Arthritis Care Res (Hoboken) 2011;63:1091–7.
  8. Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet [Internet] 2018;391:2273–84. Available from: http://dx.doi.org/10.1016/S0140-6736(18)30830-4
  9. Tanaka Y, Luo Y, O’Shea JJ, Nakayamada S. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol 2022;18:133–45.
  10. Lin CM, Cooles FA, Isaacs JD. Basic Mechanisms of JAK Inhibition. Mediterr J Rheumatol 2020;31:100–4.
  11. Yang F, Lu C, Wang Y, Liu H, Leng X, Zeng X. Efficacy and safety of Janus kinase inhibitors in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Clin Rheumatol [Internet] 2023;42:1593–605. Available from: https://doi.org/10.1007/s10067-023-06529-4
  12. Lee YH, Song GG. Relative efficacy and safety of Janus kinase inhibitors for the treatment of active psoriatic arthritis: a network meta-analysis. Z Rheumatol 2023;82:408–16.
  13. Campanaro F, Batticciotto A, Zaffaroni A, Cappelli A, Donadini MP, Squizzato A. JAK inhibitors and psoriatic arthritis: A systematic review and meta-analysis. Autoimmun Rev [Internet] 2021;20:102902. Available from: https://doi.org/10.1016/j.autrev.2021.102902
  14. Cauli A, Gladman DD, Mathieu A, Olivieri I, Porru G, Tak PP, et al. Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and  OMERACT study. J Rheumatol 2011;38:898–903.
  15. Strand V, Boers M, Idzerda L, Kirwan JR, Kvien TK, Tugwell PS, et al. It’s Good to Feel Better But It’s Better To Feel Good and Even Better to Feel Good as Soon as Possible for as Long as Possible. Response Criteria and the Importance of Change at OMERACT 10. J Rheumatol 2011;38:1720-7. Available from: http://www.jrheum.org/content/38/8/1720.abstract
  16. Chandran V, Bhella S, Schentag C, Gladman DD. Functional Assessment of Chronic Illness Therapy-Fatigue Scale is valid in patients with psoriatic arthritis. Ann Rheum Dis [Internet] 2007;66:936-9. Available from: http://ard.bmj.com/content/66/7/936.abstract
  17. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy (New York) [Internet] 1990;16:199–208. Available from: https://www.sciencedirect.com/science/article/pii/0168851090904219
  18. Strand V, de Vlam K, Covarrubias-Cobos JA, Mease PJ, Gladman DD, Chen L, et al. Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond. RMD Open 2019;5:e000808.
  19. Strand V, de Vlam K, Covarrubias-Cobos JA, Mease PJ, Gladman DD, Graham D, et al. Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL  Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs. RMD Open 2019;5:e000806.
  20. Leng X, Lin W, Liu S, Kanik K, Wang C, Wan W, et al. Efficacy and safety of tofacitinib in Chinese patients with active psoriatic arthritis: a phase 3, randomised, double-blind, placebo-controlled study. RMD Open 2023;9.
  21. Strand V, Mease PJ, Soriano ER, Kishimoto M, Salvarani C, Saffore CD, et al. Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis  Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1. Rheumatol Ther 2021;8:1789–808.
  22. Strand V, Van den Bosch F, Ranza R, Leung YY, Drescher E, Zueger P, et al. Patient-Reported Outcomes in Psoriatic Arthritis Patients with an Inadequate  Response to Biologic Disease-Modifying Antirheumatic Drugs: SELECT-PsA 2. Rheumatol Ther 2021;8:1827–44.
  23. Orbai A-M, Ogdie A, Gossec L, Tillett W, Leung YY, Gao J, et al. Effect of filgotinib on health-related quality of life in active psoriatic  arthritis: a randomized phase 2 trial (EQUATOR). Rheumatology (Oxford) 2020;59:1495–504.
  24. Mease PJ, Deodhar AA, van der Heijde D, Behrens F, Kivitz AJ, Neal J, et al. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II  trial in psoriatic arthritis. Ann Rheum Dis 2022;81:815–22.
  25. Mease P, Helliwell P, Silwinska-Stanczyk P, Miakisz M, Ostor A, Peeva E, et al. Efficacy and Safety of the TYK2/JAK1 Inhibitor Brepocitinib for Active Psoriatic  Arthritis: A Phase IIb Randomized Controlled Trial. Arthritis Rheumatol (Hoboken, NJ) 2023;75:1370–80.
  26. Gu Q, Kanungo J. Effect of ketamine on gene expression in zebrafish embryos. J Appl Toxicol 2021;41:2083–9.
  27. Al-Samhari MM, Al-Rasheed NM, Al-Rejaie S, Al-Rasheed NM, Hasan IH, Mahmoud AM, et al. Possible involvement of the JAK/STAT signaling pathway in  N-acetylcysteine-mediated antidepressant-like effects. Exp Biol Med (Maywood) 2016;241:509–18.
  28. Nicolas CS, Amici M, Bortolotto ZA, Doherty A, Csaba Z, Fafouri A, et al. The role of JAK-STAT signaling within the CNS. JAKSTAT 2013;2:e22925.
  29. Kumar S, Mehan S, Narula AS. Therapeutic modulation of JAK-STAT, mTOR, and PPAR-γ signaling in neurological  dysfunctions. J Mol Med (Berl) 2023;101:9–49.
  30. Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol 2010;9:807–19.
  31. Tsuda M, Kohro Y, Yano T, Tsujikawa T, Kitano J, Tozaki-Saitoh H, et al. JAK-STAT3 pathway regulates spinal astrocyte proliferation and neuropathic pain  maintenance in rats. Brain 2011;134:1127–39.
  32. Molet J, Mauborgne A, Diallo M, Armand V, Geny D, Villanueva L, et al. Microglial Janus kinase/signal transduction and activator of transcription 3  pathway activity directly impacts astrocyte and spinal neuron characteristics. J Neurochem 2016;136:133–47.
  33. Shamail GMH, Haridoss M, Natarajan M, Joshua V, Bagepally BS. Association Between Janus Kinase Inhibitors Therapy and Mental Health Outcome in  Rheumatoid Arthritis: A Systematic Review and Meta-analysis. Rheumatol Ther. England; 2022;9:313–29.
  34. Shariq AS, Brietzke E, Rosenblat JD, Pan Z, Rong C, Ragguett RM, et al. Therapeutic potential of JAK/STAT pathway modulation in mood disorders. Rev Neurosci 2018 Dec 19;30(1):1-7. Available from: https://doi.org/10.1515/revneuro-2018-0027
  35. Gulbins A, Grassmé H, Hoehn R, Kohnen M, Edwards MJ, Kornhuber J, et al. Role of Janus-Kinases in Major Depressive Disorder. Neurosignals. Switzerland; 2016;24:71–80.
  36. Gałecka M, Szemraj J, Su K-P, Halaris A, Maes M, Skiba A, et al. Is the JAK-STAT Signaling Pathway Involved in the Pathogenesis of Depression? J Clin Med 2022;11.
  37. Malemud CJ, Miller AH. Pro-inflammatory cytokine-induced SAPK/MAPK and JAK/STAT in rheumatoid arthritis and the new anti-depression drugs. Expert Opin Ther Targets [Internet] 2008;12:171–83. Available from: https://doi.org/10.1517/14728222.12.2.171
  38. Nash P, Dutz JP, Peterson S, Patel BP, Eaton K, Shawi M, et al. Systematic literature review and network meta-analysis of therapies for psoriatic arthritis on patient-reported outcomes. BMJ Open [Internet] 2023;13:e062306. Available from: http://bmjopen.bmj.com/content/13/11/e062306.abstract
  39. Tóth L, Juhász MF, Szabó L, Abada A, Kiss F, Hegyi P, et al. Janus Kinase Inhibitors Improve Disease Activity and Patient-Reported Outcomes in  Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of 24,135 Patients. Int J Mol Sci 2022;23.